The pan-HDAC inhibitor panobinostat acts as a sensitizer for erlotinib activity in EGFRmutated and -wildtype non-small cell lung cancer cells

The receptor tyrosine kinase (RTK) EGFR is overexpressed and mutated in NSCLC. These mutations can be targeted by RTK inhibitors (TKIs) such as erlotinib. Chromatin-modifying agents may offer a novel therapeutic approach by sensitizing tumor cells to TKIs.